ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

CINC CinCor Pharma Inc

29.06
0.00 (0.00%)
14 Jan 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
CinCor Pharma Inc NASDAQ:CINC NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 29.06 26.58 29.48 0 00:00:00

CinCor Pharma to Present at Upcoming Piper Sandler and Evercore ISI Investor Conferences

22/11/2022 11:44pm

GlobeNewswire Inc.


CinCor Pharma (NASDAQ:CINC)
Historical Stock Chart


From Jan 2022 to Jan 2025

Click Here for more CinCor Pharma Charts.

CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will present at the following investor conferences in November:

Event:Piper Sandler 34th Annual Healthcare Conference
Date:November 29 – December 1, 2022
Location:Lotte New York Palace in New York, New York
Presentation:Tuesday, November 29, 2022 at 1:30pm EST
Webcast:https://event.webcasts.com/starthere.jsp?ei=1585686&tp_key=3261cabcd6
  
Event:Evercore ISI 5th Annual HealthCONx Conference
Date:November 30 – December 1, 2022
Location:Virtual
Presentation:Thursday, December 1, 2022 at 3:30pm EST
Webcast:https://wsw.com/webcast/evercore29/cinc/2336910

The CinCor management team will participate in one-on-one investor meetings during these events. Investors interested in meeting with CinCor at the conference should contact their Piper Sandler or Evercore ISI representative. An archived replay of the presentations will be available for 90 days at CinCor.com/events.

About CinCorCinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, baxdrostat, a highly selective, oral small molecule inhibitor of aldosterone synthase, is in clinical development for the treatment of hypertension and primary aldosteronism.

Contacts: Investors:
Michael KalbBob Yedid
CinCor Pharma, Inc.LifeSci Advisors
EVP and CFO  ir@CinCor.com

1 Year CinCor Pharma Chart

1 Year CinCor Pharma Chart

1 Month CinCor Pharma Chart

1 Month CinCor Pharma Chart

Your Recent History

Delayed Upgrade Clock